The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody

Hum Immunol. 1998 Jun;59(6):352-62. doi: 10.1016/s0198-8859(98)00030-5.

Abstract

The regulation of phenotype and function of human liver infiltrating lymphocytes (LIL) by in vitro culture with IL-2, IL-12 and anti-CD3 monoclonal antibodies (mAb) was investigated. The CD3+ LIL which express 50% less CD3 molecules per cell than peripheral blood T lymphocytes, exhibited a 6-fold reduction in proliferation when stimulated through the CD3 complex by anti-CD3 mAb. LIL freshly isolated or cultured in medium did not suppress MLR response, nor were they cytotoxic. However, treatment of the LIL cells with IL-2, IL-12 and anti-CD3 induced these cells to suppress autologous responding cells in MLR (ca. 70%) and to kill autologous or allogeneic cells. Low level cytotoxicity could be induced by cytokines IL-2, IL-12 or anti-CD3 alone. However, the development of optimum MLR suppression and cytotoxicity induction was dependent upon stimulation of the LIL cells through the CD3 complex. The co-expression of CD3 and CD56 on LIL was also up-regulated by anti-CD3 stimulation in the combination of IL-2 and IL-12. Most of the CD3+/CD56+ cells, also expressed CD8. After the magnetic bead separation procedure, the cytotoxic activity was found mainly in the CD3+/CD56+/CD8+ population. These results suggest that CD3+/CD56+/CD8+ cells can be expanded by stimulation through the TCR/CD3 complex in the presence of IL-2 and IL-12, which results in the suppression of autologous responding cells by a cytotoxic mechanism. The proliferative response of the CD3+/CD56+/CD8+ population was enhanced by the induction of CD1 molecules on the stimulating cells, and anti-CD1 mAb were able to block the response in a dose-dependent manner. The CD3+/CD56+/CD8+ cells were examined for cytokine production by flow cytometry. Cytokines IL-4, TNF-alpha, and IFN-gamma were produced by 91.7%, 29.2%, and 27.4% of the cells, respectively.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antigens, CD1 / immunology
  • CD3 Complex / immunology*
  • CD56 Antigen / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Division
  • Cytotoxicity Tests, Immunologic
  • Humans
  • Immunophenotyping
  • Interferon-gamma / biosynthesis
  • Interleukin-12 / immunology*
  • Interleukin-12 / pharmacology
  • Interleukin-2 / immunology*
  • Interleukin-2 / pharmacology
  • Interleukin-4 / biosynthesis
  • Leukocytes, Mononuclear / immunology
  • Liver / cytology
  • Receptor-CD3 Complex, Antigen, T-Cell / immunology
  • Spleen / cytology
  • T-Lymphocytes / immunology*
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Antibodies, Monoclonal
  • Antigens, CD1
  • CD3 Complex
  • CD56 Antigen
  • Interleukin-2
  • Receptor-CD3 Complex, Antigen, T-Cell
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • Interleukin-4
  • Interferon-gamma